Table 3.

Hemodynamic and inflammatory biomarkers, metabolic changes, and blood platelet count during oXiris-CHFA treatment.

Parameter	Baseline (n = 90)	12 h (n = 85)	24 h (n = 75)	p value
MAPa, mmHg	75.16 [66.00–84.00]	79.33 [73.00–85.84]	82.00 [77.67–88.67]	< 0.001
Norepinephrine dosagea, μg/kg/min	0.65 [0.14–1.50]	0.40 [0.12–1.00]	0.25 [0.00–0.70]	<0.001
HRa, per min	122.00 [102.75–136.50]	101.00 [87.50–119.00]	96.00 [80.00–109.00]	<0.001
RRa, per min	23.00 [19.75–29.00]	20.00 [16.50–21.00]	18.00 [16.00–20.00]	<0.001
SOFAb	14 [10.00–17.00]	–	11.00 [9.00–15]	<0.001
Lactatea, mmol/L	5.15 [2.78–8.65]	3.6 [2.05–7.40]	3.20 [2.20–4.80]	0.008
Procalcitonina, ng/mL	23.70 [3.31–81.07]	12.9 [2.47–59.75]	11.90 [5.08–41.90]	<0.001
Interleukin-6a, pg/mL	1986.50 [555.25–5000.00]	1245.00 [292.00–5000.00]	361.50 [138.75–1051.00]	<0.001
Blood platelet counta, 109/L	83.50 [28.75–143.50]	–	44.00 [22.00–90.00]	<0.001

oXiris-CHFA, continuous hemofiltration adsorption with oXiris; MAP, mean arterial pressure; HR, heart rate; RR, respiratory rate; SOFA, Sequential Organ Failure Assessment. Non-normally distributed measurement data were expressed as median [interquartile range].

^aFriedman's test for comparison between three groups.

^bWilcoxon symbol rank test for comparison between two groups.

p value < 0.05 was considered as a significant difference.